BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-102@pharmaconomics
DTSTAMP:20260707T014530Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:SNY Phase 2 — Frexalimab
DESCRIPTION:Phase 2 trial results for Frexalimab in Type 1 Diabetes Mellitus are due Apr 28\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06111586\n\nTrack it: https://pharmaconomics.com/e/102
URL:https://pharmaconomics.com/e/102
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SNY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR